查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2092663

發炎性腸道疾病治療市場：按類型、藥物類別、給藥途徑、分銷管道、國家和地區分類－全球產業分析、市場規模、市場佔有率及2026年至2033年預測

Inflammatory Bowel Disease Treatment Market, By Type, By Drug Class, By Route of Administration, By Distribution Channel, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 333 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，發炎性腸道疾病治療市場價值將達到 243.062 億美元，並將在 2026 年至 2033 年期間以 6.1% 的複合年成長率成長。

發炎性腸道疾病 (IBD) 治療市場正經歷顯著的變化。過去，治療重點主要集中在少數幾種抑制 TNF 的傳統藥物。如今，作用機轉各異的藥物選擇更多了。阿達木單抗 (Humira) 曾經是領軍藥物。然而，近年來湧現出許多新的療法，包括 IL-23 抑制劑、JAK 抑制劑、S1P 受體調變器以及新型整合素標靶治療。這種轉變是免疫系統疾病治療領域變革的一部分。 IBD 影響超過 0.7% 的美國人，其發病率在青年時期達到高峰，之後趨於穩定。這是一種慢性終身疾病，需要持續治療而非短期介入。因此，發炎性腸道疾病已成為免疫學領域競爭最激烈的領域之一。

發炎性腸道疾病治療市場—市場動態

生物製藥的早期應用正在推動市場成長。

醫生們開始在疾病的不同階段使用生物製藥療法。在此之前，這些療法僅用於對其他治療無效的患者。然而，現在基於臨床證據表明生物療法可以預防腸道損傷並提高長期緩解的可能性，因此醫生開始更早使用生物療法。這種方法稱為「標靶治療」。自2023年以來，美國食品藥物管理局（FDA）已批准了Skyrizi、Omvoh和Rinvoq等療法用於治療發炎性腸道疾病，進一步擴大了胃腸病學家可根據患者個體情況選擇的一線治療方案範圍。

隨著越來越多的克隆氏症和潰瘍性大腸炎治療藥物獲批，醫生們越來越傾向於將生物製藥作為第一線治療方案。根據克隆氏症症和結腸炎基金會統計，美國約有310萬成年人患有發炎性腸道疾病（IBD），這是一個龐大的患者群體，他們有望從早期生物製藥治療中獲益。正因如此，發炎性腸道疾病治療市場正在不斷擴張。

發炎性腸道疾病治療市場—細分分析：

全球發炎性腸道疾病治療市場按疾病類型、藥物類別、給藥途徑、分銷管道和地區進行細分。

綜觀各種疾病，克隆氏症的治療極為困難。這是因為該疾病會影響消化道的多個部位，並可能導致瘻管和狹窄等併發症。這些併發症需要使用生物製藥進行一段時間的治療。根據美國疾病管制與預防中心（CDC）的數據，一項針對聯邦醫療保險受益人的調查顯示，2001年至2018年間，克隆氏症的盛行率以每年3.4%的速度成長。在許多國家，潰瘍性大腸炎克隆氏症更為常見。根據美國國立衛生研究院（NIH）發布的基於人群的數據，澳洲潰瘍性大腸炎的盛行率為每10萬人334例，而克隆氏症的盛行率為每10萬人306例。

從藥物類別來看，克隆氏症和潰瘍性大腸炎的第一線治療通常包括氨基水楊酸類藥物和皮質類固醇。根據美國胃腸病學會 (AGA) 和歐洲克隆氏症和結腸炎組織 (ECCO) 的說法，皮質類固醇主要用於誘導緩解，而非長期維持治療，目前正加速向生物製藥的轉變，以最大限度地減少類固醇的使用。二線治療佔據了相當大的市場。這些藥物包括白血球介素 (IL) 抑制劑、腫瘤壞死因子 (TNF) 抑制劑、JAK 抑制劑、抗整合素藥物和 S1P 受體調變器。這一領域創新層出不窮，競爭也異常激烈。根據 IQVIA 統計，在主要已開發市場，生物製藥佔發炎性腸道疾病處方藥支出的 60% 以上。 SONIC等臨床試驗表明，聯合治療可使約57%的克隆氏症患者達到無荷爾蒙緩解，而Infliximab單抗單藥治療的緩解率僅為44%。這些結果支持在部分高風險患者中繼續使用聯合治療。

發炎性腸道疾病治療市場—區域分析

北美在發炎性腸道疾病 (IBD) 治療市場佔據主導地位。這是因為北美擁有龐大的IBD患者族群、許多治療該疾病的專家，許多新型生物製藥也在此上市。根據克隆氏症症和結腸炎基金會統計，美國約有240萬人患有IBD，其中約100萬人患有潰瘍性大腸炎，約100萬人患有克隆氏症，每年新增病例數以千計。北美也是新型IBD生物製藥上市的地區。換句話說，北美患者可以比其他地區的患者更早嘗試這些療法。此類藥物包括Skyligi、Omvo、Vercipity和Entyvio。

歐洲是發炎性腸道疾病（IBD）治療市場成長最快的地區。這是因為歐洲IBD患者數量龐大，而且他們獲得所需生物製藥的途徑也越來越方便。在英國、丹麥和挪威等一些國家，潰瘍性結腸炎患者眾多。根據發表在《克隆氏症與結腸炎雜誌》上的流行病學研究，英國潰瘍性大腸炎的盛行率約為每10萬人570例，丹麥為523例，挪威為500例，這些國家的盛行率位居世界前列。這主要是由於IBD患者人數不斷增加，以及獲得必要治療的途徑日益增加。

目錄

第1章 發炎性腸道疾病治療市場概覽

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章 發炎性腸道疾病治療的主要市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：發炎性腸道疾病治療產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：發炎性腸道疾病治療市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章 發炎性腸道疾病治療市場現狀

  • 2025年發炎性腸道疾病治療市佔率分析
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章 發炎性腸道疾病治療市場：依類型分類

  • 概述
    • 基於細分市場的市場佔有率分析：按類型
    • 克隆氏症
    • 潰瘍性大腸炎

第8章 發炎性腸道疾病治療市場：依藥物類別分類

  • 概述
    • 基於細分市場的市場佔有率分析：按藥物類別分類
    • 氨基水楊酸類藥物
    • 皮質類固醇
    • TNF抑制劑
    • IL抑制劑
    • JAK抑制劑
    • 抗整合素
    • S1P受體調變器
    • 其他

第9章 發炎性腸道疾病治療市場：依給藥途徑分類

  • 概述
    • 按給藥途徑分類的市佔率分析
    • 口服
    • 注射藥物
    • 直腸給藥

第10章 發炎性腸道疾病治療市場：依分銷管道分類

  • 概述
    • 基於細分市場的市場佔有率分析：按分銷管道分類
    • 醫院藥房
    • 零售藥房
    • 網路藥房

第11章 發炎性腸道疾病治療市場：按地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 丹麥
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 台灣
    • 越南
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 伊朗
    • 卡達
    • 其他中東和非洲國家

第12章：主要供應商分析：發炎性腸道疾病治療產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • AbbVie Inc.
    • Takeda Pharmaceutical Company Limited
    • Pfizer Inc.
    • Biogen
    • Novartis AG
    • Lilly
    • UCB SA
    • CELLTRION INC.
    • Merck & Co., Inc.
    • Johnson & Johnson Services, Inc
    • Boehringer Ingelheim
    • Bausch Health Companies Inc.
    • Ferring Pharmaceuticals
    • Gilead Sciences, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Others

第13章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV6920

Inflammatory Bowel Disease Treatment Market size was valued at US$ 24,306.2 Million in 2025, expanding at a CAGR of 6.1% from 2026 to 2033.

The market for treating bowel disease is changing significantly. It used to be focus on a few old medications that blocked TNF. Now there are more options with different mechanisms of action. For a time, Humira was the leading medication. Over the past few years, new treatments have emerged. These include IL-23 inhibitors, JAK inhibitors, S1P receptor modulators and new integrin-targeted therapies. This shift is part of transformation in how we treat diseases that affect the immune system. IBD is diagnosed in over 0.7% of Americans, with incidence peaking in early adulthood before plateauing, a chronic, lifelong disease burden that sustains continuous treatment demand rather than episodic intervention. As a result, inflammatory bowel disease has become one of the competitive areas in immunology.

Inflammatory Bowel Disease Treatment Market- Market Dynamics

Early Biologic Adoption to Drive Market Growth

Physicians are starting to use biologic therapy in the disease course. They used to use it for patients who didn't respond to treatment. Now they are using it earlier because of clinical evidence that shows it can prevent bowel damage and improve long-term remission chances. This approach is called "treat-to-target". Since 2023, the U.S. Food and Drug Administration (FDA) has approved additional indications for therapies such as Skyrizi, Omvoh, and Rinvoq for inflammatory bowel diseases, giving gastroenterologists more first-line treatment options tailored to individual patient profiles.

As more treatments are approved for both Crohn's disease and ulcerative colitis doctors are becoming more comfortable using biologics as a first-line treatment. According to the Crohn's & Colitis Foundation, approximately 3.1 million adults in the United States are living with inflammatory bowel disease (IBD), representing a substantial patient population that may benefit from earlier biologic intervention. This is the reason, for the expansion of the inflammatory bowel disease treatment market.

Inflammatory Bowel Disease Treatment Market- Segmentation Analysis:

The Global Inflammatory Bowel Disease Treatment Market is segmented on the basis of Type, Drug Class, Route of Administration, Distribution Channel, and Region.

By type, Crohn's disease treatment is very tough because the condition can affect parts of the gastrointestinal tract and can cause complications like fistulas and strictures. These complications need to be controlled with biologic therapy for a time. According to the U.S. Centers for Disease Control and Prevention (CDC), a study of Medicare beneficiaries found that Crohn's disease prevalence increased at an annual percentage change (APC) of 3.4% between 2001 and 2018. Ulcerative colitis is more common than Crohn's disease in countries. Population-based data published by the National Institutes of Health (NIH) reported prevalence rates of 334 cases per 100,000 population for ulcerative colitis, compared with 306 per 100,000 for Crohn's disease in Australia.

By Drug Class, the first line of treatment for Crohn's disease and ulcerative colitis usually includes amino salicylates and corticosteroids. According to the American Gastroenterological Association (AGA) and the European Crohn's and Colitis Organization (ECCO), corticosteroids are recommended primarily for the induction of remission rather than long-term maintenance, accelerating the transition toward steroid-sparing biologic therapies. The second line of treatment is the important part of the market. It includes drugs like IL inhibitors, TNF inhibitors, JAK inhibitors, anti-integrin agents and S1P receptor modulators. This category has seen a lot of innovation and competition. According to IQVIA, biologics account for more than 60% of prescription drug spending in inflammatory bowel disease across major developed markets. Clinical trials such as SONIC demonstrated that combination therapy achieved corticosteroid-free remission in approximately 57% of Crohn's disease patients, compared with 44% receiving infliximab alone, supporting its continued use in selected high-risk patients.

Inflammatory Bowel Disease Treatment Market- Geographical Insights

North America is the leader when it comes to the market for treating IBD. This is because many people in North America have this disease there are a lot of specialists who treat it and many new biologic treatments have been launched in the United States. According to the Crohn's & Colitis Foundation, approximately 2.4 million people in the United States are living with IBD, including around 1 million with ulcerative colitis and about 1 million with Crohn's disease, with thousands of new cases diagnosed annually. North America is also the place where new IBD biologic treatments are launched. This means that people in North America get to try these treatments before anyone else. Some examples of these treatments are Skyrizi, Omvoh, Velsipity and Entyvio.

Europe is the place where the market for IBD treatment is growing the fastest. This is because many people in Europe have IBD and it is getting easier for them to access the biologic treatments they need. In some countries like the UK, Denmark and Norway many people have colitis. According to epidemiological studies published in the Journal of Crohn's and Colitis, ulcerative colitis prevalence reaches approximately 570 per 100,000 population in the United Kingdom, 523 per 100,000 in Denmark, and 500 per 100,000 in Norway, among the highest rates globally. This is because more people have IBD and it is getting easier for them to get the treatments they need.

Inflammatory Bowel Disease Treatment Market- Competitive Landscape:

The competition in this field is mostly controlled by AbbVie Inc. AbbVie Inc. has really changed its portfolio of immunology treatments with Skyrizi and Rinvoq. The company now markets therapies across multiple mechanisms of action, including TNF inhibition (Humira), IL-23 inhibition (Skyrizi), and JAK inhibition (Rinvoq), allowing physicians greater flexibility in treatment sequencing. Skyrizi was approved in 2024 to treat moderate to ulcerative colitis.

Takeda Pharmaceutical Company Limited is also major player in this field. Takeda Pharmaceutical Company Limited is working to keep its position by making improvements to Entyvio and making it available in forms. This includes treatments for both colitis and Crohn's disease. However, Takeda Pharmaceutical Company Limited is facing competition from Skyrizi and Rinvoq.

Recent Developments:

In January 2026 Boehringer Ingelheim made a deal with Sincere Pharmaceutical Group. This deal is for the world and it is about the IBD drug candidate SIM0709 that Boehringer Ingelheim is working on. The IBD drug candidate SIM0709 is really important, to Boehringer Ingelheim.

In 2024, the U.S. FDA approved AbbVie's Skyrizi for moderately to severely active ulcerative colitis, based on the INSPIRE induction and COMMAND maintenance studies, establishing it as the first IL-23 specific inhibitor approved across both major IBD indications; Japanese approval followed the same year.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Biogen
  • Novartis AG
  • Lilly
  • UCB S.A.
  • CELLTRION INC.
  • Merck & Co., Inc.
  • Johnson & Johnson Services, Inc
  • Boehringer Ingelheim
  • Bausch Health Companies Inc.
  • Ferring Pharmaceuticals
  • Gilead Sciences, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Others

GLOBALINFLAMMATORY BOWEL DISEASE TREATMENT MARKET, BY TYPE- MARKET ANALYSIS, 2020 - 2033

  • Crohn's Disease
  • Ulcerative Colitis

GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033

  • Aminosalicylates
  • Corticosteroids
  • TNF Inhibitors
  • IL Inhibitors
  • JAK Inhibitors
  • Anti-Integrin
  • S1P Receptor Modulators
  • Others

GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

  • Oral
  • Injectable
  • Rectal

GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Inflammatory Bowel Disease Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Inflammatory Bowel Disease Treatment Market Snippet by Type
    • 2.1.2. Inflammatory Bowel Disease Treatment Market Snippet by Drug Class
    • 2.1.3. Inflammatory Bowel Disease Treatment Market Snippet by Route of Administration
    • 2.1.4. Inflammatory Bowel Disease Treatment Market Snippet by Distribution Channel
    • 2.1.5. Inflammatory Bowel Disease Treatment Market Snippet by Country
    • 2.1.6. Inflammatory Bowel Disease Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Inflammatory Bowel Disease Treatment Key Market Trends

  • 3.1. Inflammatory Bowel Disease Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Inflammatory Bowel Disease Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Inflammatory Bowel Disease Treatment Market Opportunities
  • 3.4. Inflammatory Bowel Disease Treatment Market Future Trends

4. Inflammatory Bowel Disease Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Inflammatory Bowel Disease Treatment Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Inflammatory Bowel Disease Treatment Market Landscape

  • 6.1. Inflammatory Bowel Disease Treatment Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Inflammatory Bowel Disease Treatment Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2025 & 2033 (%)
    • 7.1.2. Crohn's Disease
    • 7.1.3. Ulcerative Colitis

8. Inflammatory Bowel Disease Treatment Market - By Drug Class

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Class, 2025 & 2033 (%)
    • 8.1.2. Aminosalicylates
    • 8.1.3. Corticosteroids
    • 8.1.4. TNF Inhibitors
    • 8.1.5. IL Inhibitors
    • 8.1.6. JAK Inhibitors
    • 8.1.7. Anti-Integrin
    • 8.1.8. S1P Receptor Modulators
    • 8.1.9. Others

9. Inflammatory Bowel Disease Treatment Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
    • 9.1.2. Oral
    • 9.1.3. Injectable
    • 9.1.4. Rectal

10. Inflammatory Bowel Disease Treatment Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2025 & 2033 (%)
    • 10.1.2. Hospital Pharmacy
    • 10.1.3. Retail Pharmacy
    • 10.1.4. Online Pharmacy

11. Inflammatory Bowel Disease Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Inflammatory Bowel Disease Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Inflammatory Bowel Disease Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.17. Denmark
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.17.3. Poland Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.17.4. Denmark Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.17.5. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.17.6. Denmark Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.18. Rest of Europe
      • 11.3.18.1. Overview
      • 11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.18.3. Rest of the Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.18.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.18.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.18.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Inflammatory Bowel Disease Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.16. Taiwan
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.16.3. Taiwan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.16.4. Taiwan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.16.5. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.16.6. Taiwan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.17. Vietnam
      • 11.4.17.1. Overview
      • 11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.17.3. Vietnam Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.17.4. Vietnam Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.17.5. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.17.6. Vietnam Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.18. Rest of APAC
      • 11.4.18.1. Overview
      • 11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.18.3. Rest of APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.18.4. Rest of APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.18.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.18.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Inflammatory Bowel Disease Treatment Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Inflammatory Bowel Disease Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.14. Iran
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.14.3. Iran Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.14.4. Iran Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.14.5. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.14.6. Iran Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.15. Qatar
      • 11.6.15.1. Overview
      • 11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.15.3. Qatar Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.15.4. Qatar Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.15.5. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.15.6. Qatar Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.16. Rest of MEA
      • 11.6.16.1. Overview
      • 11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.16.3. Rest of MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.16.4. Rest of MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.16.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.16.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- Inflammatory Bowel Disease Treatment Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. AbbVie Inc.
    • 12.2.2. Takeda Pharmaceutical Company Limited
    • 12.2.3. Pfizer Inc.
    • 12.2.4. Biogen
    • 12.2.5. Novartis AG
    • 12.2.6. Lilly
    • 12.2.7. UCB S.A.
    • 12.2.8. CELLTRION INC.
    • 12.2.9. Merck & Co., Inc.
    • 12.2.10. Johnson & Johnson Services, Inc
    • 12.2.11. Boehringer Ingelheim
    • 12.2.12. Bausch Health Companies Inc.
    • 12.2.13. Ferring Pharmaceuticals
    • 12.2.14. Gilead Sciences, Inc.
    • 12.2.15. Teva Pharmaceutical Industries Ltd.
    • 12.2.16. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us